Experience
University of Western Australia
Academisch Ziekenhuis Leiden
Member of team that represented Sarepta and University of Western Australia in Federal Circuit appeals from interferences related to Exondys 51® (eteplirsen) for Duchenne muscular dystrophy.
University of Western Australia v. Academisch Ziekenhuis Leiden, 16-1937, -2086, Fed. Cir.
Academisch Ziekenhuis Leiden v. University of Western Australia
University of Western Australia
University of Western Australia v. Academisch Ziekenhuis Leiden
Sarepta Therapeutics
Trading Technologies, Inc. v. CQG, Inc.
Trading Technologies, Inc.
Hillcrest Laboratories, Inc. v. Movea, Inc.
Hillcrest Laboratories, Inc.
Cox Communications v. Sprint Communication Co.
Sprint Communication Co.
Ethicon Endo-Surgery, Inc. v. Covidien LP
Covidien LP
5th Market, Inc. v. Chicago Mercantile Exchange, Inc.
Chicago Mercantile Exchange, Inc.
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
Otsuka Pharmaceutical Co., Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.